Lead Product(s): Antibody-Oligonucleotide Conjugates
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: RTW Investments
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing May 26, 2020
The funds will enable Avidity to advance Company's growing proprietary portfolio of multiple programs, including Its AOC treatment of myotonic dystrophy type I, to treat serious muscle disorder.